

1 **BDNF, inflammatory and oxidative levels in treatment-**
2 **naïve ADHD children treated with methylphenidate: An**
3 **open cohort protocol.**

4
5
6 Marina Silva de Lucca^{1¶*}, Laira Lopes Tonon^{2&}, Jordânia Alves Ferreira^{2&}, Bárbara Silva
7 Cabral^{2&}, Cleuberton Kenedy Oliveira Raimundo^{2&}, Sílvia Almeida Cardoso^{2¶}, Débora
8 Marques de Miranda^{3¶}

9
10 ¹Health Sciences Postgraduate Program, Faculty of Medicine, Federal University of
11 Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.

12 ²Department of Medicine and Nursing, Federal University of Viçosa, Minas Gerais, Brazil.

13 ³Department of Pediatrics, Faculty of Medicine, Federal University of Minas Gerais, Belo
14 Horizonte, Minas Gerais, Brazil.

15 * Corresponding author

16 E-mail: marinadelucca@ufv.br

17
18 ¶These authors contributed equally to this work.

19 &These authors also contributed equally to this work

20

21

22

23 **Abstract**

24 The attention-deficit hyperactivity disorder (ADHD) has a complex etiology,
25 involving the interaction between biological, genetic, and environmental factors. The
26 ADHD pathophysiology remains unknown even though there are hypotheses that
27 inflammatory, hormonal, oxidative and neurotrophic factors are associated. This clinical
28 trial aims to evaluate the contribution of brain derived neurotrophic factor (BDNF),
29 inflammatory and oxidative levels before and after 12 and 24 weeks of methylphenidate
30 use.

31

32 **Methods**

33 Patients will be screened upon their entry into Child and Adolescent Psychiatry
34 Teaching Outpatient Clinic of the Medical Course at the Federal University of Viçosa in
35 Minas Gerais, Brazil. One hundred and fifty ADHD treatment-naïve children of both sexes,
36 between 6–14 years old, will be invited to participate, after the ADHD diagnosis by an
37 experienced psychiatrist and the child fulfilling the inclusion criteria. Children and their
38 caregivers will answer questionnaires regarding mental health and the children will
39 undergo neuropsychological tests, physical, nutritional and activity assessment, in
40 addition to blood sampling at baseline, 12 and 24 weeks of methylphenidate use
41 respectively.

42

43 **Discussion**

44 This clinical trial intends to verify how the pharmacological treatment changes the
45 plasma BDNF, inflammatory and oxidative levels in treatment-naïve Brazilian children
46 diagnosed for ADHD.

47

48 **Trial Registration**

49 Submitted for registration on Brazilian Registry of Clinical Trials (ReBEC).

50 Trial identifier: 13612

51 Registry name: Níveis de neurotrofina, perfil inflamatório e oxidativo em crianças com
52 TDAH tratadas com metilfenidato.

53

54 **Administrative information – Spirit 2013 Checklist**

55 **Title {1}**

56 BDNF, inflammatory and oxidative levels in treatment-naïve ADHD children treated with
57 methylphenidate: An open cohort protocol.

58

59 **Trial registration**

60 **Registry {2a}**

61 Submitted for registration on Brazilian Registry of Clinical Trials (ReBEC).

62 Trial identifier: 13612.

63 Registry name: Neurotrophin level, inflammatory and oxidative profile in ADHD children
64 treated with methylphenidate.

65

66 **Data Set {2b}**

67 The Universal Trial Number (UTN) is U1111-1285-2908.

68 Date recruitment began: 23/10/2020; Approximate date when recruitment will be
69 completed: 29/11/2022.

70

71 **Protocol version {3}**

72 First version.

73 Submitted for registration on Brazilian Registry of Clinical Trials (ReBEC).

74 Trial identifier: 13612.

75

76 **Funding {4}**

77 National Council for Scientific and Technological Development (CNPQ).

78 Research Support Foundation of the State of Minas Gerais (FAPEMIG - APQ-01023/18)

79

80 **Roles and Responsibilities {5}**

81 **Contributorship {5a}**

82 Marina Silva de Lucca. Master in Physical Education and PhD student in Health Sciences,
83 Faculty of Medicine, UFMG.

84 Laira Lopes Tonon. Medicine student (UFV). Research volunteer member.

85 Bárbara Silva Cabral. Medicine student (UFV). Research volunteer member.

86 Jordânia Alves Ferreira. Medicine student (UFV). Scientific initiation scholarship
87 Cleuberton Kenedy Oliveira Raimundo. Medicine student (UFV). Research volunteer
88 member.
89 Silvia Almeida Cardoso. Master and Doctor in Immunology (USP). Associate Professor
90 of Nursing and Medicine, Faculty of Medicine, UFV.
91 Débora Marques de Miranda. Master and Doctor in Biochemical and Molecular
92 Pharmacology (UFMG). Associate Professor of Pediatrics, Faculty of Medicine, UFMG.
93 ML is the Chief Investigator; she conceived the study, led the proposal and protocol
94 development. LLT, BSC, JAF and CKOR contributed to development of the proposal and
95 methodology. SC e DM contributed to study design and to development of the proposal
96 and methodology. All authors read and approved the final manuscript.

97

98 **Sponsor contact information {5b}**

99 Not applicable.

100

101 **Sponsor and Funder {5c}**

102 This funding source had no role in the design of this study and will not have any role
103 during its execution, analyses, interpretation of the data, or decision to submit results.

104

105 **Committees {5d}**

106 **Principal Investigator and Research Physician**

107 Design and conduct the clinical appointments: Marina Silva de Lucca.

108 Preparation of protocol and revisions: Marina Silva de Lucca, Sílvia Almeida Cardoso,
109 and Débora Marques de Miranda.

110 Organizing steering committee meetings: Marina Silva de Lucca and Débora Marques de
111 Miranda.

112 Publication of study reports: Marina Silva de Lucca, Sílvia Almeida Cardoso, and Débora
113 Marques de Miranda.

114

115 **Steering committee**

116 The composition of the trial committee includes all authors.

117 Agreement of final protocol: Marina Silva de Lucca, Sílvia Almeida Cardoso, and Débora
118 Marques de Miranda.

119 All lead investigators will be steering committee members.

120 Recruitment of patients: Laira Lopes Tonon, Bárbara Silva Cabral and Jordânia Alves
121 Ferreira, Cleuberton Kenedy Oliveira Raimundo.

122 Reviewing progress of study and if necessary, agreeing changes to the protocol and/or
123 investigators brochure to facilitate the smooth running of the study: Marina Silva de Lucca
124 and Débora Marques de Miranda.

125

126 **Trial Management Committee (TMC)**

127 Study planning; Organization of steering committee meetings: Marina Silva de Lucca and
128 Débora Marques de Miranda.

129 Data verification: Marina Silva de Lucca.

130 Endpoint adjudication: Marina Silva de Lucca and Débora Marques de Miranda.

131

132 **Data Management team**

133 Data entry, data verification: Laira Lopes Tonon, Bárbara Silva Cabral, Jordânia Alves

134 Ferreira, Cleuberton Kenedy Oliveira Raimundo and Marina Silva de Lucca.

135

136 **Lead Investigators**

137 Marina Silva de Lucca, Sílvia Almeida Cardoso, and Débora Marques de Miranda.

138

139 **Schedule of enrolment, interventions, and** 140 **assessments**

141

142 **Introduction**

143

144 **Background and rationale {6a}**

145 Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder
146 characterized by symptoms of inattention, hyperactivity, and impulsivity that appear in
147 childhood and usually persist into adulthood, causing some degree of dysfunction in daily

148 activities [1,2,3]. The heterogeneous clinical presentations of ADHD are a hallmark of this
149 disorder [4] important negative outcomes are reported, both in terms of morbidity and
150 mortality [3].

151 ADHD has a complex etiology, involving the interaction between genetic, biological
152 and environmental factors. However, its pathophysiology remains unknown [5]. There are
153 hypotheses that inflammatory, oxidative, hormonal, and neurotrophic factors are
154 associated, and they have mutual interactions. [3,6].

155 Different ADHD risk factors, such as prematurity, paternal smoking, exposure to
156 pesticides and lead may be associated with common pathophysiological pathways, such
157 as inflammation, oxidative stress, and neurotrophic factors. Likewise, intrauterine pro-
158 inflammatory factors during the gestational period may be associated with restricted
159 intrauterine growth, miscarriage, premature birth, placenta abruption, neurological
160 damage, some of which are risk factors for ADHD [7,8,9, 10, 11, 12]. Neuroinflammation
161 in physiological and pathological conditions may activate microglia, astrocytes,
162 oligodendrocytes, and ependymal cells. In addition, it may increase proteases, glutamate,
163 reactive oxygen species, nitric oxide, chemokines, toxic cytokines, prostaglandins, and
164 may induces infiltration of T and B neutrophils, monocytes/ macrophages and dendritic
165 cells. When activated, these cells release pro-inflammatory cytokines that increase
166 neuroinflammation [13]. Some cytokines are elevated in ADHD, some of which are related
167 to the severity of symptoms [13, 14, 15]. A systematic review on the level of cytokines in
168 peripheral blood showed increased levels of cytokines-interleukin-6 (IL-6) in patients with
169 ADHD, especially in those younger than eighteen years and not on medication, when
170 compared to a healthy control group [13, 16]. However, another systematic review found

171 no difference in IL-6 levels when comparing children with and without ADHD [17].
172 Furthermore, patients with ADHD, especially in those younger than eighteen years and
173 not on medication, had lower levels of tumor necrosis factor-alpha human (TNF-alpha)
174 compared to healthy controls [16, 17]. The results regarding cytokines-interleukin-10 (IL-
175 10) were contradictory and may be increased or unchanged in children with ADHD
176 compared to children without the pathology [13, 16, 17]. ADHD treated patients seem to
177 have a decrease in interferon gamma (IFN-gamma) and interleukin-13 (IL-13) levels,
178 compared to those naïve to treatment [13].

179 Therefore, neuroinflammation could alter the blood-brain barrier, neurotransmitter
180 metabolism, increase oxidative stress, and neurodegeneration [14, 15]. Animals and
181 humans with ADHD show, in different brain structures, an increase in reactive oxygen
182 species without an adequate antioxidant response, resulting in an increase in oxidative
183 stress. This negative imbalance in ADHD may be explained in the central nervous system
184 due to the large consumption of oxygen by neurons associated with an antioxidant
185 defense system of modest action and a constitution rich in lipids. As a result, the brain
186 has difficulty regulating excess reactive oxygen species, making it more susceptible to
187 damage [15, 18, 19, 20, 21, 22]. Therefore, there is evidence of increased oxidative stress
188 in ADHD patients [19, 20, 21 22, 23, 24].

189 ADHD may be associated with a decrease in ascorbate, catalase, albumin and
190 bilirubin and an increase in uric acid. So, it may contribute to oxidative stress increase
191 [25]. On the other hand, treatment with methylphenidate seems to increase catalase
192 levels. Other study demonstrated that the activity of superoxide dismutase (SOD), an
193 important antioxidant defense enzyme, is lower in patients with ADHD [25].

194 Increased oxidative stress may be associated with reduced levels of BDNF, as well
195 as reduced oxidative stress with increased BDNF [26]. Therefore, changes in the BDNF
196 expression at critical moments during development may promote a cascade of events
197 interfering with the brain maturation of some regions, being a substrate for altered
198 response to stress in adulthood and development of neuropsychiatric disorders [26].
199 Another evidence of intense oxidative stress is the modulation of telomere size and
200 shortening during life [27] and telomere shortening is present in ADHD children [28]. So,
201 telomere length may be a potential biomarker of the ADHD symptoms burden in families
202 affected by this neurodevelopmental disorder [29].

203 Studies with rats have been trying to observe the results of chronic use of
204 methylphenidate in brain cells [30, 31, 32]. Chronic use of methylphenidate in healthy rats
205 caused oxidative damage in the brain of young rats [30]. Furthermore, the chronic use of
206 methylphenidate by adult rats induced oxidative stress and inflammation in the
207 hippocampus, causing cellular damage in this area [31]. Increased oxidative stress was
208 also observed in spontaneously hypertensive adult rats (animal version of ADHD) [32].

209 In ADHD children and adolescents' study, low levels of nitric oxide were found in
210 baseline, which did not change significantly with the use of methylphenidate over ten
211 weeks [33]. Guney et al. (2015) [33] found that methylphenidate may reduce oxidant
212 levels and increase antioxidant levels in children and adolescents.

213 Studies have evaluated BDNF levels in individuals with ADHD, comparing them
214 with typical children [17, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51]
215 and after stimulant treatment [40, 45, 50, 51, 52], with divergent results.

216 Due to the controversial studies and the importance of treating ADHD, this protocol
217 study aims to explain the methodology that will evaluate BDNF, inflammatory and
218 oxidative levels, their associated factors in ADHD treated children for 6 months with
219 methylphenidate.

220

221 **Choice of comparators {6b}**

222 BDNF, inflammatory markers and oxidative stress levels of the ADHD children will
223 be compared before and after methylphenidate use. Therefore, the same group of
224 children will be compared in three different times: before starting methylphenidate and
225 after 12 and 24 weeks of methylphenidate use. All patients will be in follow-up at the child
226 and adolescent psychiatry outpatient clinic, receiving pharmacological treatment for
227 ADHD. Local health system provides free methylphenidate (generic medication) in the
228 presentation of 10mg, immediate-release tablets.

229 Control groups (ADHD children without methylphenidate use) will not be
230 possible, because it would be unethical to deprive them of effective treatment, capable of
231 reducing not only morbidity, but also mortality.

232

233 **Objectives {7}**

234 The objectives of this open cohort clinical trial will be:

- 235 1. Evaluate the BDNF, inflammatory and oxidative levels before and after 12 and 24
236 weeks of methylphenidate use in treatment-naïve ADHD children.

237 2. Investigate if there is a moderating effect of the sociodemographic data, ADHD
238 presentation, comorbidity presence, caregiver psychopathology, parenting styles,
239 emotional regulation level on BDNF, cytokines and oxidative stress level, telomere
240 length, and other variables from the survey instruments detailed throughout this
241 protocol.

242

243 **Trial Design {8}**

244 This trial is designed as an open cohort, single center, with convenience sample.

245

246 **Methods: Participants, Interventions, Outcomes**

247 **Study setting {9}**

248 All subjects will be invited to the child psychiatry teaching outpatient clinic at the
249 Federal University of Viçosa (UFV), in the state of Minas Gerais, Brazil.

250

251 **Eligibility criteria {10}**

252 **Participants inclusion criteria: {10}**

253 Treatment-naïve ADHD children, of both sex in outpatient treatment; age
254 between complete 6 and incomplete 15 years old. Children must have criteria for ADHD
255 diagnosis according to the DSM-5 and must not have chronic diseases or use of any other
256 medications that may interfere with the immune system or BDNF. Children who need iron
257 or vitamin replacement may be included. The following comorbidities may be included:

258 oppositional defiant disorder (ODD), tic disorder, enuresis, encopresis, skin picking
259 disorder. Autism spectrum disorder (ASD) level 1, Classification of Diseases and Related
260 Health Problems (ICD) 10 F84.5, could be included if the diagnosis occurs during the
261 study. All parents must sign the free and informed consent form, just like children should
262 also sign the assent form. The terms will be delivered during the initial assessment of the
263 participants, if they wish to participate voluntarily in the research.

264

265 **Participants exclusion criteria: {10}**

266 Families and children that refusal to participate in the research or refusal to use
267 stimulant medications; presence of autoimmune, neurodegenerative diseases, and
268 immunodeficiencies; intellectual disability, severe clinical or psychiatric comorbidities,
269 except autism spectrum disorder level 1 (ICD 10 F84.5), ODD, tics, trichotillomania, skin
270 picking disorder, enuresis, and encopresis; previous or current use of stimulants or other
271 psychiatry medications; current use of medications for chronic diseases or that interfere
272 in immune system or BDNF levels (antidepressants for example); girls who have
273 menstruated; stimulant contraindication use.

274

275 **Participant timeline: {13, 14, 15, 18}**

276 Participants will be included from October 2020 to November 2022, targeting a
277 sample size of 150 children, based on sample calculation with analysis power between
278 80% and 95% of accuracy. This sample calculation was based on an article of Akay et
279 al., 2017 [37].

280 They will be forwarded by physicians, schools and psychologists from the city
281 and health region. To reach the sample number, the health units, as well as the municipal
282 education department were communicated about the research and how the children could
283 be referred for screening. There was also publicity on the local radio and the website of
284 the Federal University of Viçosa.

285 Children who are eligible for the study will be categorized by ADHD presentation,
286 disorder severity, with or without Oppositional Defiant Disorder (ODD), with or without
287 autism spectrum disorder (ASD), at any emotional dysregulation level. Their caregivers
288 will be sorted by parenting style.

289 Overall, each participant will make 8 to 10 visits during the study period.

290 The research procedure for participants at each visit are described in Fig. 2.

291 The initial assessment includes the semi-structured interview Kiddie-Schedule
292 for Affective Disorders and Schizophrenia – Present and Lifetime Version (K-Sads-PL
293 2013) [53].

294 To assess the severity of ADHD symptoms, the SNAP-IV scale, Swanson, Nolan
295 e Pelham version [54], and the Assessment Scale of Childhood and Adolescent
296 Behaviors in ADHD in a Family Environment (ETDAH-parents) [55] and ADHD Self-
297 Assessment Scale-Version for Children and Adolescents (ETDAH-Criad) [56] were
298 answered by parents and children. The SNAP-IV scale has 26 items, which also
299 investigates symptoms of a common comorbidity that is Defiant and Oppositional
300 Disorder. [54]. The ETDAH scale has one version for parents and another for the children.
301 [55,56]. The parent subscale has four subscales that investigates symptoms of
302 inattention, hyperactivity/impulsivity, emotional regulation, and adaptive behavior. The

303 children subscale has 2 subscales that investigates inattention and
304 hyperactivity/impulsivity symptoms.

305 The diagnosis will be confirmed by a interview done by a Child and Adolescent
306 Psychiatrist. Sociodemographic data was obtained from the Brazil Economic Ranking
307 Criterion and “Background information” part of the K-Sads-PL instrument (K-Sads-PL
308 2013) [53, 57, 58]. A standard record for the clinical history was constructed with data on
309 pregnancy, childbirth, neuropsychomotor development, and the child's previous and
310 family history.

311 For the care of children at the outpatient clinic, an anamnesis model was built.
312 This anamnesis also includes a habitual physical activity questionnaire [59], Brazilian food
313 safety scale [60], SISVAN food consumption markers questionnaire [61], food frequency
314 questionnaire [62, 63], bullying questionnaire (Kidscape) [64], measurement
315 questionnaire adherence to treatment [65], CRAFFT/CESARE instrument (Car; Relax;
316 Alone; Forget; Family/Friends; Trouble acronym) [66].

317 Situations of violence and/or health identified during the research will be duly
318 forwarded to the necessary assistance network, such as justice, other medical specialties,
319 social services, and others. The caregiver is screened for symptoms of depression,
320 anxiety, ADHD, and alcohol use [67, 68, 69, 70]. In case of positive screening, evaluation
321 by an adult psychiatrist will be offered.

322

323 **Interventions {11a, 18}**

324 **Screening visits**

325 Medical students trained by an experienced child and adolescent psychiatrist
326 and under her supervision, will apply in the first assessment (between one and three
327 visits): Fig. 1. Schedule of enrolment, interventions, and assessments.

328 # Multimodal Treatment Assessment Study – Swanson, Nolan e Pelham (MTA-
329 SNAP-IV) scale, that evaluates symptoms of attention deficit/hyperactivity disorder
330 and oppositional defiant disorder in children and adolescents [54]

331 # Kiddie Schedule for Affective Disorders and Schizophrenia for School Aged
332 Children – Lifetime Version (K-Sads-PL 2013) [53]

333 # Sociodemographic questionnaire, including the Brazil Economic Ranking Criterion
334 and the background information of the K-Sads-PL 2013 [53,57,58]

335 # ADHD Behavior Assessment Scale – Parents Version (ETDAH-parents) [55]

336 # Bullying questionnaire [64]

337 # Physical activity questionnaire [59]

338 # SISVAN food consumption markers [61]

339 # Brazilian Food Security Scale (EBIA) [60]

340 # Scale of Sleep disorders in children [72]

341 # Behavior Inventory for Children and Adolescents (CABI) [73]

342 # Parenting Styles and Dimensions Questionnaire – Short Version (PSDQ) [74]

343 # Epidemiological Studies Center Depression Scale (CES-D) [67]

344 # State-Trait Anxiety Inventory (IDATE) [68]

345 # Adult Self-Report Scale (ASRS-18) [69]

346 # Alcohol Use disorders identification test (AUDIT) [70]

347 # Standardized psychiatric clinic interview with standard record.

348 # Physical examination.

349

350 Psychology students, under supervision of an experienced psychologist in
351 neuropsychology will apply:

352 # Scale for screening drug use CRAFFT/CESARE [66]

353 # Social Skills Test for Children and Adolescents in School Situation (THAS-C) [75]

354 # ADHD Self-Assessment Scale – Version for Children and Adolescents (ETDAH-
355 CriAd) [56]

356 # Standardized and validated psychological tests for the Brazilian population.

357 • Non-Verbal test of Children's Reasoning (TNVRI) [76]

358 • Battery for Attention Assessment (BPA) [77, 78]

359 • Five digits teste (FDT) [79]

360 • Brief Child Neuropsychological Assessment Instrument (NEUPSILIN-inf)
361 [80]

362

363 Nutrition's student under supervision of an experienced nutritionist will apply:

364 # 24-hour food recall [81, 82]

365

366 **Assessment points {11a, 18a}**

367 The assessment points occur in three timepoints: baseline (before
368 methylphenidate initial use) and after 12 and 24 weeks of methylphenidate use. Fig 1
369 and 2.

370 In the first assessment point the blood sample is collected, the family receives
371 psychoeducation about the disorder and its treatment, and the methylphenidate is started.

372 In the second and third assessment points, all instruments will be applied in
373 screening are reapplied, except K-Sads-PL, sociodemographic questionnaire,
374 standardized psychiatric clinic interview with standard record and NEUPSILIN-inf. In
375 these two timepoints, we will use standardized follow-up anamnesis. Participants will also
376 be clinically evaluated to verify the effect of the treatment (the Clinical Global Impressions
377 (CGI) scale) [83, 84, 85], dose adjustment, the presence of adverse effects, adherence
378 to treatment, clarification of doubts regarding the research, the disorder, and the
379 treatment and reinforce the guidelines regarding the next steps of the study.

380

381 **Follow-up visits {11a, 18a}**

382 Participants will also be clinically evaluated at 4, 8 and 18 weeks to verify the
383 effect of the treatment, dose adjustment, the presence of adverse effects, adherence to
384 treatment, clarification of doubts regarding the research, the disorder, the treatment and
385 reinforce the guidelines regarding the next steps of the study.

386 The number of visits could vary, depending on the patient's individual needs.

387 **Pharmacotherapy {11b}**

388 Pharmacotherapy will be conducted by experienced child and adolescent
389 psychiatry with primary responsibility for childcare.

390 Pharmacotherapy starts with a first-line stimulant medication methylphenidate.
391 [86]. The initial dose will be prescribed as follows: 5mg in the morning and after lunch in

392 the first week, with adjustment to 10mg at the same time until the next evaluation at 4
393 weeks. From that moment on, the dose will be titrated to optimize the desired therapeutic
394 effect and minimize undesirable adverse effects. The average dose will be 1 mg/kg/day.

395 If the child does not tolerate the methylphenidate [87, 88] or does not respond to
396 medication, lisdexamfetamine will be offered. [88] Other formulations may be used such
397 as methylphenidate hydrochloride extended-release capsules or OROS methylphenidate
398 if necessary. In these cases, equivalent doses will be prescribed.

399

400 **Blood sample {11a}**

401 A trained nursing professional will collect three samples of venous blood from
402 each patient/volunteer: before medication treatment, 12 and 24 weeks after starting
403 treatment. Blood samples will be kept at a suitable temperature [89] until they are sent to
404 the Biochemistry laboratory of the Department of Biochemistry (UFV). The BDNF [90] and
405 the cytokines levels [91, 92, 93, 94] will be evaluated in blood plasma and the oxidative
406 stress [95,96] level will be evaluated in serum. Telomeres measurements will be made by
407 DNA extraction [27, 28, 29].

408

409 **Adherence to intervention protocols {11c, 18b}**

410 To improve adherence to medical visits and research evaluations, nursing
411 technique will confirm the consultation by telephone (calls or WhatsApp messages) the
412 day before. In case of participant absence, contact by phone will be made to offer
413 appointment rescheduling.

414 The assessment methylphenidate adherence will be by pill count and the
415 Treatment Adherence Measure (MAT) questionnaire [65] in all scheduled visits [97].

416

417 **Modifications {11b}**

418 The participant will be excluded from the survey if he does not attend the
419 assessment points (blood collection times). If the patient reports the impossibility of
420 attending the assessment visit and is available to reschedule it within a maximum of 15
421 days, the patient can proceed with the intervention. The patient may miss the visits
422 number 4, 8, 18 and proceed with the intervention, if the regular use of medication
423 continues.

424 The child will be excluded in case of not tolerating the medication, family
425 withdraws from participation, diagnosis change during follow-up.

426 The pharmacological intervention may have adverse effects and the child will
427 receive all the necessary and standard care following strictly the clinical protocol. Most
428 adverse effects are usually mild and occur early in treatment [87]. They will be informed
429 and medication will be adjusted accordingly the need.

430 Participants whose diagnosis on screening differs from the diagnosis of the
431 psychiatry team will be excluded from the study.

432

433 **Concomitant care {11d}**

434 The treatment can also include speech therapy and occupational therapy if there
435 is a clinical indication. The psych treatment was not available.

436

437 **Outcomes {12}**

438 **Primary outcomes:**

439 The BDNF levels [37], cytokines and level of oxidative stress (oxidative and
440 antioxidant substances) after treatment with methylphenidate.

441

442 **Secondary outcomes:**

443 Behavioral symptoms of Attention Deficit/Hyperactivity Disorder and/or
444 Oppositional Defiant Disorder, emotional regulation level determined by the Multimodal
445 Treatment Assessment Study - Swanson, Nolan e Pelham (MTA-SNAP-IV) scale, which
446 assesses symptoms of attention deficit/hyperactivity disorder and Oppositional Defiant
447 Disorder in children and adolescents, and ETDAH - parents, which assesses emotional
448 regulation.

449 Cardiovascular parameters on physical examination, as well as body mass index
450 will be recorded.

451

452 **Retention {18b}**

453 The intervention has the potential to bring great benefits to the child and whole
454 family. The stimulant treatment in ADHD children is associated with reduced morbidity
455 and mortality.

456 WhatsApp contact will be possible for participants to clarify their doubts,
457 reschedule the appointment, as well as be reminded of the appointments during the
458 period in which they participate in the study.

459 Moreover, a report containing the child's neuropsychological assessment will be
460 given to the parents. In addition, all children will be under medical supervision at the
461 outpatient clinic, even after the end of the study (UFV).

462 Post-intervention measures will not be necessary after the twenty-fourth week.
463 The analysis will be performed with the information obtained up to the time of dropping
464 out in case of child drops out of the study.

465

466 **Data Management {19}**

467 A part of the data will be entered electronically and registered in REDCap
468 database. A random sampling checking will be done to quality control.

469 Participant research files are attached to their medical records, so they will be
470 kept for 20 years after the last registration.

471

472 **Statistical Methods {20}**

473 **Outcomes {20a}**

474 The main analysis strategies will involve group comparison from the three
475 timepoints and trajectory of symptoms and measures across time. Generalized
476 Estimating Equations (GEE) analyses may be done with risk factors and potential

477 moderators such social deprivation, parental styles, and oppositional symptoms to
478 understand the relationship.

479

480 **Additional analyses {20b}**

481 The main additional analyses strategies will involve descriptive data to
482 characterize the studied sample and to observe the correlations between features.

483

484 **Analysis Population and Missing Data {20c}**

485 Individuals that will not fill the information of the primary outcomes will have the
486 other data analyzed: sociodemographic profile, BDNF dosages, cytokines, and oxidative
487 stress at baseline to understand potential populational bias.

488 Missing data will be handled as necessary for the chosen tests, for GEE for
489 example we will include only individuals with the complete data set for primary outcomes.
490 We will try to retrieve all information by WhatsApp contact.

491

492

493 **Methods: Monitoring**

494 **Data Monitoring {21}**

495 **Formal Committee {21a}**

496 Diagnosis data was done by thirteen years experienced child psychiatry and there
497 is a team on UFMG to discuss any doubt prof. DMM and AASJ. They also have 15 years
498 of experience in the field.

499

500 **Interim Analyses {21b}**

501 Individuals that will not fill the information of the primary outcomes will have the
502 other data analyzed: sociodemographic profile, BDNF dosages, cytokines, and oxidative
503 stress at baseline.

504 Socioeconomic data will be analyzed to evaluate any potential of sampling bias.

505 The clinical psychiatric assessment will be done by an experienced child and
506 adolescent psychiatry, and any diagnosis divergence will be informed. Adherence will be
507 considered poor if the child takes less than 2/3 of prescribed doses of methylphenidate.

508

509 **Harms {22}**

510 Adverse events during the trial will be registered in the child's medical record and
511 communicated to the relevant governmental agencies if necessary.

512 Assistance in case of adverse events will be guaranteed to the child via the public
513 health system.

514

515 **Auditing {23}**

516 All data will be available to audit if necessary. The diagnosis divergence will be
517 evaluated and informed as soon as it is verified.

518

519 **Ethics and Dissemination**

520 **Research Ethics Approval {24}**

521 Approved by the Research Ethics Committee of the Federal University of Minas
522 Gerais. Number: 4.364.744. CAAE: 82870117.0.3001.5149. Written, informed consent
523 to participate will be obtained from all parents, as well as informed assent from the
524 children.

525

526 **Protocol Amendments {25}**

527 Any modifications to the protocol which may impact on the conduct of the study,
528 potential benefit of the patient or may affect patient safety, will lead to a formal
529 amendment to the protocol with REBEC, the ethics committee and clinical trial publication
530 journal.

531

532 **Consent or Assent {26}**

533 **Consent or Assent {26a}**

534 All parents must sign the free and informed consent form, as well as the children the
535 assent form. The terms will be delivered at the end of the child's screening if the child is
536 considered eligible to be included in the study and they wish to participate voluntarily in
537 the research.

538

539 **Ancillary Studies {26b}**

540 Not Applicable

541

542 **Confidentiality {27}**

543 All study-related information will be stored securely at the child’s medical record.

544 All local databases will be secured with password-protected access systems.

545

546 **Declaration of Interests {28}**

547 The author(s) declare(s) that they have no competing interests.

548

549 **Access to Data {29}**

550 All researchers will have access to the final trial dataset without any contractual
551 limitations.

552

553 **Ancillary and Post-trial Care {30}**

554 The children will continue clinical treatment at the child psychiatry outpatient
555 clinic for as long as the family wishes, or they will be discharged or reach the age of 18,
556 when they will be referred to adult services.

557

558 **Dissemination Policy {31}**

559 **Trial Results {31a}**

560 All research data and personal information will be under responsibility of the
561 researchers to protect confidentiality before, during and after the trial. All parents or
562 guardians' results will be communicated at the end and regarding the trial results.

563 Trial results will be published at REBEC, regardless of the magnitude or direction
564 of effect. The results will also be reported in an original article and submitted for a relevant
565 journal.

566

567 **Authorship {31b}**

568 ML is the Chief Investigator; she conceived the study, led the proposal and protocol
569 development. L, B and J contributed to development of the proposal and methodology.
570 SC e DMM contributed to study design and to development of the proposal and
571 methodology. All authors will read and approve the final manuscript.

572

573 **Reproducible Research {31c}**

574 The anonymous data information might be available under request and reasonable
575 demand.

576

577 **Discussion**

578 Inflammatory, neurotrophic, and oxidative parameters have been associated with
579 the pathophysiology of ADHD. Limitations in the studies varies from small and

580 heterogeneous samples of participants [12], lack of control for variables that may interfere
581 with the results, such as diet, body mass index, short follow-up time, and level of physical
582 activity, are some of these limitations. Moreover, the results are contradictory [98]. Here
583 we propose a protocol trying to make clear clinical and biomarkers in response to
584 medication in a cohort well characterized in a prospective follow up.

585 Many studies were cross-sectional and retrospective, which allows inferring only
586 an association between inflammation and the disorder and not a causal relationship of
587 pathogenesis [98]. Longitudinal studies are necessary to better establish the possible
588 relationship between ADHD, inflammation, neurotrophic, and oxidative stress [16]. Other
589 important factors to be considered are comorbid mental disorders and potential
590 confounding factors, in addition to being important to observe possible changes in the
591 inflammatory profile after interventions [16].

592 This trial protocol methodology will follow the participants by 24 weeks, increasing
593 the chance of evaluating the influence of the chronic use of methylphenidate on
594 inflammatory, neurotrophic, and oxidative factors. In addition, there will be evaluation of
595 the child's diet and physical activity through the food recall and the usual physical activity
596 questionnaire, respectively. To reduce hormonal influences of puberty, we will exclude
597 girls who had menarche and limited the age of both sexes to 14 years.

598 The results may provide information about the pathophysiology of ADHD, being able
599 to collaborate in the identification of biomarkers of the disorder and response to treatment
600 with methylphenidate.

601

602

603 **Acknowledgements**

604 Acknowledgment to the entire Specialized Health Care team (UAES/UFV),
605 Biochemistry and Medicine laboratory (UFV) team, Molecular Medicine laboratory
606 (UFMG) team, scientific initiation students (UFV), psychology students (volunteer
607 member/Univiçosa), nutrition professor and student (UFV), the neuropsychologist
608 Roselaine da Cunha Barros (volunteer member), and the nursing techniques Arieta de
609 Jesus Felisberto Oliveira (UFV) e Ana Cristine Pepe Parabocz (UFV).

610

611 **Appendices**

612

613 **Appendix 1. Informed consent materials {32}**

614

615 **Appendix 2. Consent and Assent forms {32}**

616 **Appendix 3. Biorepository constitution {32}**

617

618 **Biological specimens {33}**

619 Collection and analysis of biological samples will follow standard protocols for
620 these procedures in accordance with health surveillance recommendations.

621 Biorepository term was signed and contains the norms of storage and use in
622 auxiliary and future studies. (Appendix 3)

623

624 **References**

- 625 1. Biederman J, Faraone S. Attention-deficit Hyperactivity Disorder. *Lancet*. 2005;
626 (9481):237–248.
- 627 2. Edition F. *Diagnostic and Statistical Manual of Mental Disorders*. American
628 Psychiatric Association. 2013; 21.
- 629 3. Sharma A, Couture J. A Review of the Pathophysiology, Etiology, and Treatment
630 of Attention-Deficit Hyperactivity Disorder (ADHD). *Annals of Pharmacotherapy*.
631 2013 Nov;48(2):209–25.
- 632 4. Drechsler R, Brem S, Brandeis D, Grünblatt E, Berger G, Walitza S. ADHD:
633 Current Concepts and Treatments in Children and Adolescents. *Neuropediatrics*
634 [Internet]. 2020 Oct 1;51(5):315–35.
- 635 5. Núñez-Jaramillo L, Herrera-Solís A, Herrera-Morales WV. ADHD: Reviewing the
636 Causes and Evaluating Solutions. *Journal of Personalized Medicine*. 2021 Mar
637 1;11(3):166.
- 638 6. Dursun S, Demirci E, Kilic E, Ozmen S. A Different View on the Etiopathogenesis
639 of Attention-deficit Hyperactivity Disorder from an Inflammation Perspective.
640 *Clinical Psychopharmacology and Neuroscience*. 2021 Feb 28;19(1):145–54.
- 641 7. Larson K, Russ SA, Kahn RS, Halfon N. Patterns of Comorbidity, Functioning, and
642 Service Use for US Children With ADHD, 2007. *Pediatrics* [Internet]. 2011 Mar
643 1;127(3):462–70.
- 644 8. Heyer DB, Meredith RM. Environmental toxicology: Sensitive periods of
645 development and neurodevelopmental disorders. *NeuroToxicology*. 2017 Jan;
646 58:23–41.

- 647 9. Sogard AS, Mickleborough TD. The therapeutic potential of exercise and caffeine
648 on attention-deficit/hyperactivity disorder in athletes. *Frontiers in Neuroscience*.
649 2022 Aug 12;16.
- 650 10. Lopresti AL. Oxidative and nitrosative stress in ADHD: possible causes and the
651 potential of antioxidant-targeted therapies. *ADHD Attention Deficit and*
652 *Hyperactivity Disorders*. 2015 Apr 19;7(4):237–47.
- 653 11. Abdollahi M, Ranjbar A, Shadnia S, Nikfar S, Rezaie A. Pesticides, and oxidative
654 stress: a review. *Medical Science Monitor: International Medical Journal of*
655 *Experimental and Clinical Research [Internet]*. 2004 Jun 1;10(6):RA141-147.
- 656 12. Dunn GA, Nigg JT, Sullivan EL. Neuroinflammation as a risk factor for attention
657 deficit hyperactivity disorder. *Pharmacology Biochemistry and Behavior [Internet]*.
658 2019 Jul; 182:22–34.
- 659 13. Anand D, Colpo GD, Zeni G, Zeni CP, Teixeira AL. Attention-
660 Deficit/Hyperactivity Disorder and Inflammation: What Does Current Knowledge
661 Tell Us? A Systematic Review. *Front Psychiatry*. 2017; 8: 228.
- 662 14. Noakes PS, Thomas R, Lane C, Mori TA, Barden AE, Devadason SG, et al.
663 Association of maternal smoking with increased infant oxidative stress at 3 months
664 of age. *Thorax [Internet]*. 2007 Aug 1 [cited 2021 Aug 1];62(8):714–7.
- 665 15. Alvarez-Arellano L, González-García N, Salazar-García M, Corona JC. Antioxidants as
666 a Potential Target against Inflammation and Oxidative Stress in Attention-
667 Deficit/Hyperactivity Disorder. *Antioxidants*. 2020 Feb 21;9(2):176.
- 668 16. Misiak B, Wójta-Kempa M, Samochowiec J, Schiweck C, Aichholzer M, Reif A,
669 Samochowiec A, Stańczykiewicz B. Peripheral blood inflammatory markers in

- 670 patients with attention deficit/hyperactivity disorder (ADHD): A systematic review
671 and meta-analysis. *Progress in Neuro-Psychopharmacology Biological Psychiatry*.
672 2022; 118.
- 673 17. Chang JP, Mondelli V, Satyanarayanan SK, Chiang YJ, Chen HT, Su KP, Pariante
674 CM. Cortisol, inflammatory biomarkers and neurotrophins in children and
675 adolescents with attention deficit hyperactivity disorder (ADHD) in Taiwan. *Brain*,
676 behavior, and immunity. 2020; 88:105–113.
- 677 18. Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine
678 oxidase inhibitors. *Nature Reviews Neuroscience* [Internet]. 2006 Apr 1;7(4):295–
679 309.
- 680 19. Leffa DT, Bellaver B, de Oliveira C, de Macedo IC, de Freitas JS, Grevet
681 EH, Caumo W, Rohde LA, Quincozes-Santos A, Torres ILS. Increased Oxidative
682 Parameters and Decreased Cytokine Levels in an Animal Model of
683 AttentionDeficit/Hyperactivity Disorder. *Neurochemical research*, 2017; 42(11):
684 30843092. DOI: 10.1007/s11064-017-2341-6.
- 685 20. Annelies V, Harry R, Annelies B, Tess DB, Nina H. Evaluation of Biomarkers of
686 Oxidative Stress in Attention-Deficit/ Hyperactivity Disorder (ADHD). *Journal of*
687 *Molecular Biomarkers & Diagnosis*. 2018;09(03).
- 688 21. Joseph N, Zhang-James Y, Perl A, Faraone SV. Oxidative Stress and ADHD.
689 *Journal of Attention Disorders*. 2013 Nov 14;19(11):915–24.
- 690 22. Sezen H, Kandemir H, Savik E, Basmacı Kandemir S, Kilicaslan F, Bilinc H, et al.
691 Increased oxidative stress in children with attention deficit hyperactivity disorder.
692 *Redox Report*. 2016 Feb 18;21(6):248–53.

- 693 23. Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-
694 Quiroga JA, et al. Attention-deficit/hyperactivity disorder. *Nature Reviews Disease*
695 *Primers* [Internet]. 2015 Aug 6; 1:15020.
- 696 24. Wynchank D, Bijlenga D, Beekman AT, Kooij JJS, Penninx BW. Adult Attention-
697 Deficit/Hyperactivity Disorder (ADHD) and Insomnia: an Update of the Literature.
698 *Current Psychiatry Reports*. 2017 Oct 30;19(12).
- 699 25. Lu Z, Pu C, Zhang Y, Sun Y, Liao Y, Kang Z, et al. Oxidative Stress and Psychiatric
700 Disorders: Evidence from the Bidirectional Mendelian Randomization Study.
701 *Antioxidants*. 2022; 11:1386.
- 702 26. Asghari A, Hosseini M, Beheshti F, Shafei MN, Mehri S. Inducible nitric oxide inhibitor
703 aminoguanidine, ameliorated oxidative stress, interleukin-6 concentration, and
704 improved brain-derived neurotrophic factor in the brain tissues of neonates born from
705 titanium dioxide nanoparticles exposed rats. *The Journal of Maternal-Fetal &*
706 *Neonatal Medicine*. 2018 Jun 17;32(23):3962–73.
- 707 27. Drury SS, Theall K, Gleason MM, Smyke AT, De Vivo I, Wong JY et al. Telomere
708 length and early severe social deprivation: linking early adversity and cellular
709 aging. *Molecular Psychiatry*. 2012; 17(7): 719-27.
- 710 28. Pham C, Vryer R, O'Hely M, Mansell T, Burgner D, Collier F et al., On Behalf of
711 The Barwon Infant Study Investigator Group. Shortened Infant Telomere Length Is
712 Associated with Attention Deficit/Hyperactivity Disorder Symptoms in Children at
713 Age Two Years: A Birth Cohort Study. *International Journal of Molecular Sciences*.
714 2022; 23(9): 4601.

- 715 29. Costa DS, Rosa DV, Barros AG, Romano-Silva MA, Malloy-Diniz LF, Mattos P et
716 al. Telomere length is highly inherited and associated with hyperactivity-impulsivity
717 in children with attention deficit/hyperactivity disorder. *Frontiers in Molecular*
718 *Neuroscience*. 2015; 8: 28.
- 719 30. Martins M, Reinke A, Petronilho F, Gomes K, Dal-Pizzol F, Quevedo J.
720 Methylphenidate treatment induces oxidative stress in young rat brain. *Brain*
721 *research*. 2006; 1078: 189-197.
- 722 31. Motaghinejad M, Montevalian M, Shabab B. Effects of chronic treatment with
723 methylphenidate on oxidative stress and inflammation in hippocampus of adult
724 rats. *Neuroscience letters*. 2016; 619: 106-113.
- 725 32. Comim CM, Gomes KM, Réus GZ, Petronilho F, Ferreira GK, Streck EL,
726 Dal-Pizzol F, Quevedo J. Methylphenidate treatment causes oxidative stress and
727 alters energetic metabolism in an animal model of attention-deficit hyperactivity
728 disorder. *Acta Neuropsychiatrica*. Cambridge University Press. 2014; 26(2): 96-
729 103.
- 730 33. Doneray E, Yazici KU, Yazici IP, Ustundag B. Altered Arginine/Nitric Oxide
731 Pathway in Children Diagnosed Attention Deficit Hyperactivity Disorder, and the
732 Effect of 10 Weeks Methylphenidate Treatment. *Clinical Psychopharmacology and*
733 *Neuroscience*. 2022; 20(2): 350-363.
- 734 34. Guney E, Cetin FH, Alisik M, Tunca H, Tas Torun Y, Iseri E, et al. Attention Deficit
735 Hyperactivity Disorder and oxidative stress: A short term follow up study.
736 *Psychiatry Research*. 2015 Sep;229(1-2):310–7.

- 737 35. Shim SH, Hwangbo Y, Kwon YJ, Jeong HY, Lee BH, Lee HJ, Kim YK. Increased
738 levels of plasma brain-derived neurotrophic factor (BDNF) in children with attention
739 deficit-hyperactivity disorder (ADHD). *Progress in NeuroPsychopharmacology and*
740 *Biological Psychiatry*. 2008; 32(8):1824–1828.
- 741 36. Sayyah, H. BDNF plasma level in ADHD children: correlation to different
742 symptomatology. *Curr Psychiatry [Egypt]*, 2009; 16, 284-294.
- 743 37. Sargin E, Akay AP, Resmi H, Cengizhan SA, Ozek H, Ellidokuz H, Miral S, Orcin
744 E. Evaluation of Serum Brain-Derived Neurotrophic Factor Levels in Children with
745 Attention Deficit Hyperactivity Disorder: Preliminary Data. *Archives of*
746 *Neuropsychiatry*. 2012; 49(2): 96+.
- 747 38. Scassellati C, Zanardini R, Tiberti A, Pezzani M, Valenti V, Effedri P, Filippini E,
748 Conte S, Ottolini A, Gennarelli M, Bocchio-Chiavetto L. Serum brain-derived
749 neurotrophic factor (BDNF) levels in attention deficit-hyperactivity disorder
750 (ADHD). *European child & adolescent psychiatry*. 2013; 23(3): 173-177.
- 751 39. Liu L, Li H, Wang Y, Yang L, Qian Q, Wang Y. Association between GUC2C and ADHD:
752 evidence from both categorical and quantitative traits. *Psychiatry Research [Internet]*.
753 2014 Dec 15 [cited 2023 Feb 12];220(1-2):708–10.
- 754 40. Sahin S, Yuce M, Alacam H, Karabekiroglu K, Say GN, Salis O. Effect of
755 methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin,
756 and brain-derived neurotrophic factor in children and adolescents with attention
757 deficit and hyperactivity disorder. *International journal of psychiatry in clinical*
758 *practice*. 2014; 18(4): 280–287.

- 759 41. Saadat F, Kosha M, Amiry A, Torabi G. Brain-Derived Neurotrophic Factor as a
760 Biomarker in Children with Attention Deficit-Hyperactivity Disorder. *Journal of*
761 *Krishna Institute of Medical Sciences University*. 2015; 4(4): 10-17.
- 762 42. Imşek Ş, Gençoğlan S, Yüksel T, Kaplan İ, Aktaş H, Alaca R. Evaluation of the
763 Relationship between Brain-Derived Neurotrophic Factor Levels, and the Stroop
764 Interference Effect in Children with Attention-Deficit Hyperactivity Disorder. *Noro*
765 *Psikiyatri Arsivi*. 2016; 53(4): 348–352.
- 766 43. Bilgiç A, Toker A, Işık Ü, Kılınç İ. Serum brain-derived neurotrophic factor, glial-
767 derived neurotrophic factor, nerve growth factor, and neurotrophin-3 levels in
768 children with attention-deficit/hyperactivity disorder. *European child & adolescent*
769 *psychiatry*. 2017; 26(3): 355–363.
- 770 44. Reda M, El-Nady HG, Rabie MA, Fawzy R, Adel S, AwadAllah E, Moneim MA.
771 Comparing brain-derived neurotrophic factor levels, intelligence, and memory in
772 clinical subtypes of attention-deficit hyperactivity disorder. *Middle East Current*
773 *Psychiatry*. 2016; 23(2): 56-62.
- 774 45. Cubero-Millán I, Ruiz-Ramos MJ, Molina-Carballo A, Martínez-Serrano S,
775 Fernández-López L, Machado-Casas I, Tortosa-Pinto P, Ruiz-López A, LunaDel-
776 Castillo JD, Uberos J, Muñoz-Hoyos A. BDNF concentrations and daily fluctuations
777 differ among ADHD children and respond differently to methylphenidate with no
778 relationship with depressive symptomatology. *Psychopharmacology*. 2016;
779 234(2): 267–279
- 780 46. Taha H, Elsheshtawy E, Mohamed SI, Al-Azazzy O, Elsayed M, Ibrahim SAS.
781 Correlates of brain derived neurotrophic factor in children with attention deficit

- 782 hyperactivity disorder: A case-control study. *Egyptian Journal of Psychiatry*. 2017;
783 38(3): 159-163.
- 784 47. Wang LJ, Wu CC, Lee MJ, Chou MC, Lee SY, Chou WJ. Peripheral Brain Derived
785 Neurotrophic Factor and Contactin-1 Levels in Patients with Attention
786 Deficit/Hyperactivity Disorder. *Journal of clinical medicine*. 2019; 8(9):1366.
- 787 48. Yurteri N, Şahin İE, Tufan AE. Altered serum levels of vascular endothelial growth
788 factor and glial-derived neurotrophic factor but not fibroblast growth factor2 in
789 treatment-naive children with attention deficit/hyperactivity disorder. *Nordic journal
790 of psychiatry*. 2019; 73(4-5): 302–307.
- 791 49. El Ghamry R, El-Sheikh M, Meguid MA, Nagib S, El Gabry DA. Plasma brain
792 derived neurotrophic factor (BDNF) in Egyptian children with attention deficit
793 hyperactivity disorder. *Middle East Current Psychiatry*. 2021; 28: 22.
- 794 50. Gumus C, Yazici IP, Yazici KU, Ustundag B. Increased Serum Brain-derived
795 Neurotrophic Factor, Nerve Growth Factor, Glial-derived Neurotrophic Factor and
796 Galanin Levels in Children with Attention Deficit Hyperactivity Disorder, and the
797 Effect of 10 Weeks Methylphenidate Treatment. *Clinical psychopharmacology and
798 neuroscience: the official scientific journal of the Korean College of
799 Neuropsychopharmacology*. 2022; 20(4): 635–648.
- 800 51. Akay AP, Resmi H, Güney SA, Erkuran HÖ, Özyurt G, Sargin E, et al. Serum brain-
801 derived neurotrophic factor levels in treatment-naïve boys with attention-
802 deficit/hyperactivity disorder treated with methylphenidate: an 8-week,
803 observational pretest–posttest study. *European Child & Adolescent Psychiatry*.
804 2017 Jul 14;27(1):127–35.

- 805 52. Amiri A, Torabi Parizi G, Kousha M, Saadat F, Modabbernia MJ, Najafi K, Atrkar
806 Roushan Z. Changes in plasma Brain-derived neurotrophic factor (BDNF) levels
807 induced by methylphenidate in children with Attention deficit-hyperactivity disorder
808 (ADHD). *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2013;
809 47: 20-24.
- 810 53. Caye A, Kieling RR, Rocha TB, Graeff-Martins AS, Geyer C, Krieger F, et al.
811 Schedule for Affective Disorders and Schizophrenia for School-Age Children –
812 Present and Lifetime Version (K-SADS-PL), DSM-5 update: translation into
813 Brazilian Portuguese. *Brazilian Journal of Psychiatry*. 2017 Dec;39(4):384–6.
- 814 54. Mattos P, Serra-Pinheiro MA, Rohde LA, Pinto D. A Brazilian version of the MTA-
815 SNAP-IV for evaluation of symptoms of attention-deficit/hyperactivity disorder and
816 oppositional-defiant disorder. *Revista de psiquiatria do Rio Grande do Sul*.
817 2006;28(3):290-7.
- 818 55. Benczik E. Escala de avaliação dos comportamentos infantojuvenis no TDAH em
819 ambiente familiar - Versão para pais (ETDAH-PAIS). 1st ed. Vol. 1. Memnon;
820 2018.
- 821 56. Benczik E. Escala de Autoavaliação do TDAH-Versão para crianças e
822 adolescentes (ETDAH-Criad). 1st ed. Vol. 1. Memnon; 2018.
- 823 57. Kamakura W, Mazzon JA. Socioeconomic Stratification Criteria and Classification
824 Tools in Brazil. *Revista de administração de empresas*. 2016; 56:55-70.
- 825 58. Associação Brasileira de Empresas de Pesquisa (ABEP). Alterações na aplicação
826 do Critério Brasil, válidas a partir de 16/04/2018. 2018.

- 827 59. Fernandes C. Validação do questionário de avaliação de atividade física em
828 crianças com idade entre 9 e 10 anos. Vitória. Tese [Mestrado em Educação
829 Física] – Universidade Federal do Espírito Santo; 2012.
- 830 60. Ministério do Desenvolvimento e Combate à fome - Secretaria de Avaliação e
831 Gestão da Informação (MDS-SAGI). Escala brasileira de Insegurança Alimentar
832 (EBIA): análise psicométrica de uma dimensão da Segurança Alimentar e
833 Nutricional. Estudo técnico nº1/2014.
- 834 61. Ministério da Saúde. Orientações para avaliação de marcadores de consumo
835 alimentar na atenção básica. 2015, access on feb 11 of 2023]. Available on
836 [https://bvsmms.saude.gov.br/bvs/publicacoes/marcadores_consumo_alimentar_at](https://bvsmms.saude.gov.br/bvs/publicacoes/marcadores_consumo_alimentar_at_encao_basica.pdf)
837 [encao_basica.pdf](https://bvsmms.saude.gov.br/bvs/publicacoes/marcadores_consumo_alimentar_at_encao_basica.pdf)
- 838 62. Gibson RS, Ferguson EL. An interactive 24-hour recall for assessing the adequacy
839 of iron and zinc intakes in developing countries. Washington, DC, and California:
840 International Food Policy Research Institute (IFPRI) and International Center for
841 Tropical Agriculture (CIAT). 2008.
- 842 63. Gibson RS, Charrondiere UR, Bell W. Measurement errors in dietary assessment
843 using self-reported 24-hour recalls in low-income countries and strategies for their
844 prevention. *Advances in Nutrition*. 2017;8(6):980-991.
- 845 64. Kidscape: preventing bullying, protecting children. [Accessed on feb 11 of 2013].
846 Available on <http://www.kidscape.org.uk/> Access on: 11/02/2023.
- 847 65. Delgado AB, Lima ML. Contribution to Concurrent Validity of Treatment
848 Adherence. *Psicologia, Saúde e Doenças*. 2001;2(2):81-100.

- 849 66. Pereira BA de AX, Schram PFC, Azevedo RCS de. Evaluation of the Brazilian
850 version of the CRAFFT/CESARE scale for screening drug use by adolescents.
851 *Ciência & Saúde Coletiva*. 2016 Jan;21(1):91–9.
- 852 67. Silveira DX, Jorge MR. Psychometric properties of the epidemiologic screening
853 scale for depression (CES-D) in clinical and non-clinical populations of adolescents
854 and young adults. *Revista de psiquiatria clínica (São Paulo)*; 1998; 25(5):251-61.
- 855 68. Biaggio AMB, Natalício L, Spielberger CD. Desenvolvimento da forma
856 experimental em português do Inventário de Ansiedade Traço-Estado (IDATE).
857 Rio de Janeiro. *Arquivos brasileiros de psicologia*. 1977; 29 (3): 3144.
- 858 69. Leite WB. Avaliação das propriedades psicométricas da escala de autorrelato de
859 sintomas do transtorno do déficit de atenção e hiperatividade ASRS-18. Belo
860 Horizonte. Tese [Mestrado em Neurociências] - Universidade Federal de Minas
861 Gerais. 2011.
- 862 70. Mendéz, EB. Uma versão brasileira do AUDIT (Alcohol use disorders identification
863 test). Pelotas. Tese [Mestrado em Epidemiologia] - Universidade Federal de
864 Pelotas. 1999.
- 865 71. Costa DS, Paula JJ de, Malloy-Diniz LF, Romano-Silva MA, Miranda DM. Parent
866 SNAP-IV rating of attention-deficit/hyperactivity disorder: accuracy in a clinical
867 sample of ADHD, validity, and reliability in a Brazilian sample. *Jornal de Pediatria*.
868 2019 Nov;95(6):736–43.
- 869 72. Ferreira V. Escala de distúrbios do sono em crianças: tradução, adaptação cultural
870 e validação. São Paulo. Tese [Mestrado em Ciências] – Universidade Federal de
871 São Paulo - Escola Paulista de Medicina. 2009.

- 872 73. Cianchetti C, Pasculli M, Pittau A, Campus MG, Carta V, Littarru R, et al. Child and
873 Adolescent Behavior Inventory (CABI): Standardization for age 6-17 Years and
874 First Clinical Application. *Clinical Practice & Epidemiology in Mental Health*. 2017
875 Mar 22;13(1):20–6.
- 876 74. Oliveira TD, Costa DS de, Albuquerque MR, Malloy-Diniz LF, Miranda DM, de
877 Paula JJ. Cross-cultural adaptation, validity, and reliability of the Parenting Styles
878 and Dimensions Questionnaire – Short Version (PSDQ) for use in Brazil. *Revista*
879 *Brasileira de Psiquiatria*. 2018 Jun 11;40(4):410–9.
- 880 75. Bartholomeu D, Silva MCR da, Montiel JM. Teste de habilidades sociais para
881 crianças e adolescentes em situação escolar (THAS-C). 1st ed. Vol. 1. Memnon;
882 2014.
- 883 76. Pasquali L. Manual Técnico e de Aplicação do Teste Não-Verbal de Raciocínio
884 para Crianças - TNVRI. 1st ed. Vol. 1. São Paulo - SP. Vetor editora; 2005. P.1-
885 82.
- 886 77. Rueda FJM. BPA - Bateria psicológica para avaliação da atenção. 1st ed. Vol. 1.
887 São Paulo - SP. Vetor editora; 2013.
- 888 78. Rueda FJM, Monteiro RM de. Psychological Battery for Attention Assessment
889 (BPA): performance of different age groups. *Psico-USF*. 2013;18(1):99–108.
- 890 79. Sedó M, Paula JJ de, Malloy-Diniz LF. Five Digit Test. 1st ed. Vol. 1. Hogrefe;
891 2015.
- 892 80. Salles JF de, Fonseca RP, Rodrigues CC, Mello CB, Barbosa T, Miranda MC.
893 Development of the Child Brief Neuropsychological Assessment Battery
894 NEUPSILIN-INF. *Psico-USF*. 2011; 16(3): 297-305.

- 895 81. Crispim SP et al. Manual fotográfico de quantificação alimentar. 2017. Curitiba:
896 Universidade Federal do Paraná. 2017.
- 897 82. International Dietary Data Expansion Project. 24-hour Dietary Recall (24HR).
898 [Accessed on feb 11 of 2023]. Available on
899 [https://index.nutrition.tufts.edu/data4diets/data-source/24-hour-dietary-recall-](https://index.nutrition.tufts.edu/data4diets/data-source/24-hour-dietary-recall-24hr)
900 [24hr](https://index.nutrition.tufts.edu/data4diets/data-source/24-hour-dietary-recall-24hr)
- 901 83. Guy W. Clinical Global Impression (CGI): ECDEU Assessment Manual for
902 Psychopharmacology. Department of Health, Education, and Welfare. 1976.
- 903 84. Busner J, Targum SD. The Clinical Global Impressions Scale: applying a research
904 tool in clinical practice. *Psychiatry (edgmont)*. 2007;4(7): 29-37.
- 905 85. Lima MS de et al. The Portuguese version of the Clinical Global Impression –
906 Schizophrenia Scale: validation study. *Revista Brasileira de Psiquiatria*.
907 2007;29(3):246-9
- 908 86. Advokat C, Scheithauer M. Attention-deficit hyperactivity disorder (ADHD)
909 stimulant medications as cognitive enhancers. *Frontiers in Neuroscience*.
910 2013;7(82).
- 911 87. Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, et al.
912 Methylphenidate for children and adolescents with attention deficit hyperactivity
913 disorder (ADHD). *Cochrane Database of Systematic Reviews*. 2015 Nov 25.
- 914 88. Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al.
915 Comparative efficacy, and tolerability of medications for attention-deficit
916 hyperactivity disorder in children, adolescents, and adults: a systematic review and
917 network meta-analysis. *Lancet Psychiatry*. 2018 Sep;5(9):727-738.

- 918 89. Lin SK, Tsai SM, Huang JC, Lee SC, Wu SH, Wu SH, et al. Effects of storage time
919 and temperature on the stability of glutathione in deproteinized blood samples.
920 Journal of Food and Drug Analysis. 2020 Jul 14;14(2).
- 921 90. Gejl AK, Enevold C, Bugge A, Andersen MS, Nielsen CH, Andersen LB.
922 Associations between serum and plasma brain-derived neurotrophic factor and
923 influence of storage time and centrifugation strategy. Scientific Reports. 2019; 9:
924 9655.
- 925 91. de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V. Prerequisites
926 for cytokine measurements in clinical trials with multiplex immunoassays. BMC
927 Immunology. 2009;10(1):52.
- 928 92. Aziz N, Detels R, Quint JJ, Li Q, Gjertson D, Butch AW. Stability of cytokines,
929 chemokines and soluble activation markers in unprocessed blood stored under
930 different conditions. Cytokine. 2016 Aug; 84:17–24.
- 931 93. Gong Y, Liang S, Zeng L, Ni Y, Zhou S, Yuan X. Effects of blood sample handling
932 procedures on measurable interleukin 6 in plasma and serum. Journal of Clinical
933 Laboratory Analysis. 2019 May 26;33(7).
- 934 94. Chiswick EL, Duffy E, Japp B, Remick D. Detection and Quantification of Cytokines
935 and Other Biomarkers. Methods in Molecular Biology [Internet]. 2011 Dec 21; 844:15–
936 30.
- 937 95. Jansen EHJM, Beekhof PK, Cremers JWJM, Viezeliene D, Muzakova V, Skalicky
938 J. Short-Term Stability of Biomarkers of Oxidative Stress and Antioxidant Status in
939 Human Serum. ISRN Biomarkers. 2013 Jun 18; 2013:1–5.

- 940 96. Jansen EHJM, Beekhof PK, Viezeliene D, Muzakova V, Skalicky J. Long-term
941 stability of oxidative stress biomarkers in human serum. *Free Radical Research*.
942 2017 Nov 28;51(11-12):970–7.
- 943 97. Osterberg L, Blaschke T. Adherence to Medication. *The New England Journal of*
944 *Medicine*. 2005; 353:487-97.
- 945 98. Cortese S et al. Candidate diagnostic biomarkers for neurodevelopmental
946 disorders in children and adolescents: a systematic review. *World Psychiatry*.
947 2023; 22(1): 129-149.

948

949 **Supporting Information**

950 S1_File. SPIRIT Checklist.

Fig 1. Schedule of enrolment, interventions, and assessments.

| TIMEPOINT** | STUDY PERIOD | | | | | | | |
|--|--------------|------------|-------------------|----------------|----------------|-----------------|-----------------|-----------------|
| | Enrolment | Allocation | Post-allocation | | | | | Close-out |
| | $-t_1$ | t_0 | t_1 baseline | t_2 4 sem | t_3 8 sem | t_4 12 sem | t_5 18 sem | t_6 24 sem |
| ENROLMENT: | | | | | | | | |
| Eligibility screen | X | | | | | | | |
| K-Sads-PL | X | | | | | | | |
| Sociodemographic data | X | | | | | | | |
| Allocation | | X | | | | | | |
| INTERVENTIONS: | | | | | | | | |
| Child Questionnaires | | | | | | | | |
| ADHD Self-Assessment Scale – Version for Children and Adolescents (ETDAH-Cri Ad) | | | X | | | X | | X |
| ADHD Behavior Assessment Scale - Parental Version (ETDAH-parents) | | | X | | | X | | X |
| SNAP-IV | | | X | | | X | | X |
| Psychiatry interview (standard record) | | | X | X | X | X | X | X |
| Physical Examination | | | X | X | X | X | X | X |
| Measure Treatment Adherence (MTA) and pill count | | | X | X | X | X | X | X |
| 24-hour food recall | | | X | | | X | | X |
| SISVAN food consumption markers | | | X | | | X | | X |
| Bullying questionnaire (Kidscape) | | | X | | | X | | X |
| Physical activity questionnaire | | | X | | | X | | X |


medRxiv preprint doi: <https://doi.org/10.1101/2023.03.03.23286780>; this version posted March 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

| | | | | | | | | |
|---|--|--|---|---|---|---|---|---|
| Scale of sleep disorders in children | | | X | | | X | | X |
| Social Skills Test for Children and Adolescents in School Situation (THAS-C) | | | X | | | X | | X |
| CRAFFT/CESARE (scale for screening drug use) | | | X | | | X | | X |
| CABI (Behavior Inventory for Children and Adolescents) | | | X | | | X | | X |
| Caregivers Questionnaires | | | | | | | | |
| Parenting Styles and Dimensions Questionnaire – Short Version (PSDQ) | | | X | | | X | | X |
| medRxiv preprint doi: https://doi.org/10.1101/2023.03.03.23286780 ; this version posted March 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . | | | X | | | X | | X |
| Epidemiological Studies Center Depression Scale (CES-D) | | | X | | | X | | X |
| State-Trait Anxiety Inventory (IDATE) | | | X | | | X | | X |
| Audit (Alcohol Use Disorder Identification Test) | | | X | | | X | | X |
| Asr18 (Adult Self-Report Scale) | | | X | | | X | | X |
| Neuropsychological Assessment | | | | | | | | |
| TNVRI | | | X | | | X | | X |
| BPA | | | X | | | X | | X |
| FDT | | | X | | | X | | X |
| Neupsilin | | | X | | | | | |
| Pharmacological Intervention | | | | | | | | |
| Methylphenidate (short acting) | | | X | X | X | X | X | X |
| Sample Blood | | | | | | | | |
| BDNF | | | X | | | X | | X |
| Cytokines | | | X | | | X | | X |
| Oxidative stress | | | X | | | X | | X |
| ASSESSMENTS: | | | | | | | | |

| | | | | | | | | |
|---------------------------------------|--|--|---|--|--|---|--|---|
| <i>First trial assessment</i> | | | X | | | | | |
| <i>Second trial assessment</i> | | | | | | X | | |
| <i>Third trial assessment</i> | | | | | | | | X |

medRxiv preprint doi: <https://doi.org/10.1101/2023.03.03.23286780>; this version posted March 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).

Fig. 2. The participants visit.



* Assessment points (Psychiatric clinical follow-up, Nutrition assessment, Neuropsychological assessment, Sample Blood, Questionnaires and Scales)

** Methylphenidate prescription after first blood sample.

***Children who finished the trial times will be transferred to the general outpatient clinic of child psychiatry at the UFV medical school.